Why it matters
The fight over Medicare funding and regulations threatens Humana’s core business.
By the numbers
Humana boasted an 82% quarter-over-quarter increase
- $2.88 million: Humana’s total Q1 2025 lobbying expenditure
- 82.3%: Increase from Q4 2024’s $1.58 million spending
- $2.51 million: In-house lobbying expenditures, up from $1.27 million
- Six external lobbying firms retained, including two recent additions
The big picture
Humana’s lobbying surge comes as Congress debates concurrent budget resolutions (H.Con.Res.14 and S.Con.Res.7) that could fundamentally reshape healthcare funding through reconciliation instructions.
Democrats have claimed the resolutions would "pillage our government and plunder peoples’ healthcare," with Congressman Chris Deluzio calling it a "fiscally reckless grift." Republican supporters, including Representative Franklin, counter that the budget delivers on an "America First agenda."
Zoom in
Humana’s lobbying targets a broad portfolio of healthcare issues including:
- Medicare Advantage policy and reimbursement rates;
- Medicare Part D prescription drug program changes;
- Implementation of the Inflation Reduction Act’s drug pricing provisions;
- Pharmacy Benefit Manager (PBM) regulations;
- Prior authorization rules and CMS interoperability requirements, and
- Veterans and TRICARE healthcare systems
Between the lines
The Louisville-based insurer’s heightened focus on budget resolutions reveals its strategy to shape the fiscal environment underpinning federal health spending before specific program details are finalized.
The explicit lobbying on CMS risk adjustment data validation (RADV) audits highlights Humana’s concern about potential financial clawbacks from the government.
Who else is in the game
Humana isn’t alone on the healthcare lobbying battlefield:
- The American Medical Association and Federation of American Hospitals represent providers who often have competing interests with insurers
- AARP advocates for Medicare beneficiaries
- Other major corporations including Lockheed Martin and FedEx are also lobbying on the budget resolutions
Behind the lobbying operation
Humana employs veteran lobbyists with deep institutional knowledge:
- Jeffrey E. Lungren, with lobbying experience dating back to 2010
- Rachel Leed Magnuson, who has represented Humana since 2014
- Tiffany McGuffee Haverly, former Communications Director for the House Energy and Commerce Committee
The company recently added Brownstein Hyatt Farber Schreck LLP and Tiber Creek Group Inc. to its roster of external firms, suggesting a strategic expansion of its influence capabilities.
The bottom line
Humana’s extraordinary lobbying investment reflects the high-stakes policy environment for Medicare Advantage insurers, who face potential payment cuts, increased regulatory scrutiny, and structural reforms that could fundamentally impact their business model.
Spot something wrong? Report an issue with this article